Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
Gregorc V, Citterio G, Vitali G, Spreafico A, Scifo P, Borri A, Donadoni G, Rossoni G, Corti A, Caligaris-Cappio F, Maschio AD, Esposito A, De Cobelli F, Dell'acqua F, Troysi A, Bruzzi P, Lambiase A, Bordignon C.
Eur J Cancer. 2009 Nov 7. [Epub ahead of print]PMID: 19900802 [PubMed - as supplied by publisher]Related articles